In this issue:
Salvage therapy options after CAR T cell relapse
Cilta-cel elicits responses in noncellular BCMA-targeted exposed patients
Delayed transplant after induction adversely impacts PFS
Risk factors for infection during RVd induction
Belantamab plus dexamethasone for triple-class RRMM
Iberdomide combo has activity in pretreated late-line RRMM
Variation in radiation therapy fractionation for MM in Australia
Deep learning may help identify sarcopenia with prognostic potential
Patients with MM at risk for severe COVID-19
Differentiating pseudo-progression after CAR T cell therapy
Please login below to download this issue (PDF)